Advertisement

Topics

Palbociclib Misses OS Endpoint in PALOMA-3 Breast Cancer Study

12:51 EDT 25 Jun 2018 | OncLive

The combination of palbociclib (Ibrance) and fulvestrant (Faslodex) failed to improve overall survival compared with fulvestrant and placebo in the phase III PALOMA-3 trial for patients with HR-positive, HER2-negative metastatic breast cancer.

Original Article: Palbociclib Misses OS Endpoint in PALOMA-3 Breast Cancer Study

NEXT ARTICLE

More From BioPortfolio on "Palbociclib Misses OS Endpoint in PALOMA-3 Breast Cancer Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...